CORRECTION

Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD

Rebecca Hall · Mark G. Lebwohl · Andrew G. Bushmakina ·
Eric L. Simpson · Melinda J. Gooderham · Andreas Wollenberg ·
Adam Gater · Jane R. Wells · Joseph C. Cappelleri · Ming-Ann Hsu ·
Jocelyn Papacharalambous · Elena Peeva · Anna M. Tallman ·
Weidong Zhang · Linda Chen

Published online: June 28, 2021
© The Author(s) 2021

Correction to: Dermatol Ther (Heidelb) (2021) 11:221–233
<https://doi.org/10.1007/s13555-020-00474-9>

The authors would like to publish an erratum to the above article.

The Discussion section of the original publication previously said:

Furthermore, PSAAD was developed to meet regulatory guidance and—unlike POEM, Itch Numeric Rating Scale (v2.0), Skin Pain Numeric Rating Scale (v2.0b), and Peak Pruritus Numerical Rating Scale—to be included in product-labelling claims in the USA and Europe.

The original article can be found online at <https://doi.org/10.1007/s13555-020-00474-9>.

R. Hall (✉) · A. Gater · J. R. Wells
Patient-Centered Outcomes, Adelphi Values, Adelphi
Mill, Bollington, Cheshire, UK
e-mail: rebecca.hall@adelphivalues.com

M. G. Lebwohl
Kimberly and Eric J. Waldman Department of
Dermatology, Icahn School of Medicine at Mount
Sinai, New York, NY, USA

A. G. Bushmakina
PIH Statistics, Pfizer Inc., Groton, CT, USA

E. L. Simpson
Department of Dermatology, Oregon Health and
Science University, Portland, OR, USA

M. J. Gooderham
SKiN Centre for Dermatology and Probiotic Medical
Research, Peterborough, ON, Canada

M. J. Gooderham
Queen's University, Kingston, ON, Canada

A. Wollenberg
Department of Dermatology and Allergy, Ludwig-
Maximilians-Universität München, Munich,
Germany

J. C. Cappelleri
Global Biometrics and Data Management, Pfizer
Inc., Groton, CT, USA

M.-A. Hsu
PIH-Global Health and Value, Pfizer Inc., Groton,
CT, USA

J. Papacharalambous · A. M. Tallman · L. Chen
Pfizer Inc., New York, NY, USA

E. Peeva
R&D-Inflammation and Immunology, Pfizer Inc.,
Cambridge, MA, USA

W. Zhang
Pfizer Inc., Cambridge, MA, USA

However, these instruments, including the Peak Pruritus Numerical Rating Scale, have either accumulated sufficient evidence to meet regulatory guidance related to product-labelling claims and/or have since been recommended for use in clinical trials. Accordingly, the specific references to these instruments should be deleted, and the sentence should read as follows:

Furthermore, PSAAD was developed to meet regulatory guidance and to be included in product-labelling claims in the USA and Europe.

The original article has been corrected.

Open Access. This article is licensed under a Creative Commons Attribution-

NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.